Abstract:BackgroundLower urinary tract symptoms (LUTS) and prostate specific antigen-based parameters seem to have only a limited utility for the differential diagnosis of prostate cancer (PCa). MALDI-TOF/MS peptidomic profiling could be a useful diagnostic tool for biomarker discovery, although reproducibility issues have limited its applicability until now. The current study aimed to evaluate a new MALDI-TOF/MS candidate biomarker.MethodsWithin- and between-subject variability of MALDI-TOF/MS-based peptidomic urine and serum analyses were evaluated in 20 and 15 healthy donors, respectively. Normalizations and approaches for accounting below limit of detection (LOD) values were utilized to enhance reproducibility, while Monte Carlo experiments were performed to verify whether measurement error can be dealt with LOD data. Post-prostatic massage urine and serum samples from 148 LUTS patients were analysed using MALDI-TOF/MS. Regression-calibration and simulation and extrapolation methods were used to derive the unbiased association between peptidomic features and PCa.ResultsAlthough the median normalized peptidomic variability was 24.9%, the within- and between-subject variability showed that median normalization, LOD adjustment, and log2 data transformation were the best combination in terms of reliability; in measurement error conditions, intraclass correlation coefficient was a reliable estimate when the LOD/2 was substituted for below LOD values. In the patients studied, 43 peptides were shared by the urine and serum, and several features were found to be associated with PCa. Only few serum features, however, show statistical significance after the multiple testing procedures were completed. Two serum fragmentation patterns corresponded to the complement C4-A.ConclusionsMALDI-TOF/MS serum peptidome profiling was more efficacious with respect to post-prostatic massage urine analysis in discriminating PCa.

Simultaneous Detection of Zinc and Its Pathway Metabolites Using MALDI MS Imaging of Prostate Tissue

Metabolomic Profiling of Prostate Cancer by Matrix Assisted Laser Desorption/ionization-Fourier Transform Ion Cyclotron Resonance Mass Spectrometry Imaging Using Matrix Coating Assisted by an Electric Field (MCAEF).

A Novel Tetrapeptide Fluorescence Sensor for Early Diagnosis of Prostate Cancer Based on Imaging Zn2+ in Healthy Versus Cancerous Cells

Development of Zinc‐Specific Icest MRI As an Imaging Biomarker for Prostate Cancer

Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery

Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy

The Use of Matrix Coating Assisted by an Electric Field (mcaef) to Enhance Mass Spectrometric Imaging of Human Prostate Cancer Biomarkers

Evaluation of Prostate Cancer Based on MALDI-TOF MS Fingerprinting of Nanoparticle-Treated Serum Proteins/peptides.

A Novel Fluorescent Probe for the Early Detection of Prostate Cancer Based on Endogenous Zinc Sensing.

Discovery and Multi-center Verification of Prostate Cancer Protein Biomarkers using Single-shot Short Gradient Microflow SWATH and MRMHR Mass Spectrometry

Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination

Urinary Zinc Loss Identifies Prostate Cancer Patients

MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers

An NMR-based metabolic signature to identify clinically significant prostate cancer in patients undergoing biopsy

Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome

Metabolic analysis using HR‐MAS in prostate tissue for prostate cancer diagnosis

Discrimination of serum samples of prostate cancer and benign prostatic hyperplasia with 1H-NMR metabolomics

Matrix- and Surface-Assisted Laser Desorption/Ionization Mass Spectrometry Methods for Urological Cancer Biomarker Discovery—Metabolomics and Lipidomics Approaches

Molecular Insights into the Breast and Prostate Cancer Cells in Response to the Change of Extracellular Zinc

Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy

A study of low-molecular-weight organic acid urinary profiles in prostate cancer by a new liquid chromatography-tandem mass spectrometry method